JP Morgan, Morgan Stanley, UBS & More Announce Massive Buybacks – The Special Situations Report Episode #26

Episode Summary

Executive Summary: Episode 26 of Special Situations Report covered a busy week in event-driven markets: Home Depot’s $110/share bid for GMS overtook QXO’s offer, Concentra Biosciences continued its string of microcap biotech acquisitions, Toma Bravo emerged as a possible buyer of Verint while also closing its Olo deal, and multiple consumer, renewable, and cross-border situations remained in play. The hosts also highlighted major buyback announcements, insider buying, activist campaigns, spin-off activity, and ongoing CEO/CFO turnover across several struggling companies.

Main Topics: Home Depot outbids QXO for GMS (Priority: 5/5): Home Depot, via SRS Distribution, signed a definitive agreement to buy GMS for $110/share in cash, eclipsing Brad Jacobs/QXO’s prior $95.20 bid and effectively ending the expected bidding war unless QXO counteroffers again. Concentra Biosciences’ biotech roll-up strategy (Priority: 5/5): Concentra Biosciences continued its monthly pattern of acquiring small, cash-rich or distressed biotech names, adding IGM Biosciences to prior deals for Alacose, Kronos Bio, and Elevation Oncology. The structure emphasizes returning cash and monetizing assets through CVRs. Toma Bravo and software M&A in AI-sensitive sectors (Priority: 4/5): Bloomberg reported Toma Bravo is negotiating a potential acquisition of Verint Systems, a call-center software company exposed to AI disruption, while Toma Bravo also completed its $2 billion all-cash acquisition of Olo. Brand and retail consolidation, including Lands’ End and Big Five Sporting Goods (Priority: 4/5): The episode highlighted competing interest in Lands’ End from Authentic Brands and WHP Global, plus the smaller cash deal for Big Five Sporting Goods by Worldwide Golf and Capital Hill Group, showing continued consolidation in retail and apparel. Major buybacks and capital returns at big banks (Priority: 4/5): JPMorgan, Morgan Stanley, and UBS announced large share repurchase programs, reflecting strong balance sheets and potentially more cautious capital deployment amid uncertainty in the economic outlook. Activism, insider buying, and governance battles (Priority: 4/5): Starboard built a stake in TripAdvisor and plans to engage management, JANA and Continental Grain secured board changes at Lamb Weston, and the Lifeway Foods family feud escalated into a fight to replace the board and restrict family involvement. Spin-offs, C-suite changes, and idiosyncratic special situations (Priority: 3/5): The episode also covered Fortive’s Ralliant spin-off, new CEO/CFO transitions at Asana, Krispy Kreme, and Ulta Beauty, and insider buying at names like Welltower, NovaGold, PVH, and Asana.

Key Arguments: Home Depot’s $110/share GMS bid makes QXO’s prior offer look inadequate, and the market’s tiny spread suggests investors do not currently expect a higher counterbid. QXO may move on to another target in construction/building products, but the strategy raises questions about overpaying and antitrust scrutiny as industry roll-ups progress. Concentra Biosciences’ model appears designed to buy undervalued biotech companies, return excess cash to shareholders, and monetize IP/product candidates rather than build drugs internally. Verint could be an attractive PE target because it is profitable, trades at low multiples, and may be vulnerable to AI-driven disruption in call-center software. Toma Bravo’s Olo acquisition shows its willingness to pay up for higher-growth software assets, even at nearly 5x trailing sales, if growth and margin profiles justify it. The battle for Lands’ End reflects broader brand-rollup behavior by Authentic Brands and WHP Global, extending beyond distressed companies to more stable but underperforming brands. Large bank buybacks signal confidence in capital strength but also possibly a more cautious stance given recent macro uncertainty and changing policy conditions. Starboard’s TripAdvisor stake may push the company toward better capital allocation and profitability, especially as AI changes consumer travel-planning behavior. The Lifeway Foods situation remains a family and governance battle as much as an M&A issue, with competing family factions taking opposing sides on the Danone bid. Welltower, NovaGold, PVH, and Asana insider purchases suggest management or board members see value in their own companies despite recent volatility or weak stock performance.

Data Points: GMS deal value: $5.5 billion - Home Depot, via SRS Distribution, agreed to acquire GMS GMS offer price: $110 per share - Cash tender offer announced by Home Depot QXO prior bid for GMS: $95.20 per share - Brad Jacobs/QXO’s earlier offer GMS premium to 60-day average: 27% - Described as the premium embedded in QXO’s prior offer GMS spread: 0.27% - Market spread after Home Depot’s announcement GMS closing timeline: by January 31, 2026 - Expected close by end of Home Depot fiscal year Big Five Sporting Goods deal value: $113 million - Worldwide Golf and Capital Hill Group acquisition Big Five Sporting Goods price: $1.45 per share - All-cash transaction Big Five deal spread: 2% - Approximate trading spread after announcement IGM Biosciences deal value: $82.85 million - Concentra Biosciences acquisition IGM cash consideration: approximately $1.25 per share - Shareholders receive cash plus CVR Concentra recent acquisitions: 4 deals in 4 months - Alacose, Kronos Bio, Elevation Oncology, and IGM Biosciences Alacose acquisition: $9 million - First of Concentra’s recent biotech deals Kronos Bio acquisition: $35 million - Second Concentra biotech deal mentioned Elevation Oncology acquisition: $21 million - Third Concentra biotech deal mentioned Verint valuation multiple: less than 1.5x trailing sales - Used to argue the company is a potentially attractive acquisition target Verint EBITDA multiple: 11x EBITDA - Valuation cited in discussion of Toma Bravo interest Olo acquisition value: $2 billion - Toma Bravo’s all-cash acquisition Olo price: $10.25 per share - Offer price in Toma Bravo deal Olo premium: about 15% - Premium to last close Lands’ End ownership by Eddie Lampert: about 17 million shares / more than 53% - Lampert’s influence over the company and the sale process Renew Energy Global proposal: $8 per share - Non-binding offer from consortium led by CPP Investments Renew Energy Global increase from prior proposal: $0.93 - Increase from December 2024 proposal Renew Energy consortium ownership: more than 58% - Bidder group already owns a majority stake CPP Investments stake: nearly 35% - Part of the consortium’s existing ownership Jumia takeover-interest financing: $600 million - Axian Telecom raised debt financing to help fund possible takeover Juniper Networks acquisition value: $14 billion - HPE deal completed after DOJ settlement Fortive spin-off ratio: 1 Ralliant share for every 3 Fortive shares - Distribution to shareholders Ralliant 2024 revenue: $2.2 billion - Size of the spun-off precision technologies business Ralliant stock move: down about 7% - Performance since spin-off Ralliant trading volume: nearly 20% of total shares traded - Post-spin activity level JPMorgan buyback program: $50 billion - Large share repurchase announcement JPMorgan buyback as % of market cap: 6% - Scale relative to company size Morgan Stanley buyback program: $20 billion - Reauthorized share purchase program Morgan Stanley buyback as % of market cap: 9% - Scale relative to company size UBS buyback announcement: $2 billion + another $2 billion later - Repurchase plan over multiple periods Asana insider purchase: 450,000 shares / $6 million - Dustin Moskovitz bought stock last week Asana share price paid: about $13 and change - Average purchase price Welltower insider purchase: about $3 million - Director Andrew Gray Luck purchase Welltower market cap: $100 billion - Discussed to show company scale Welltower revenue growth: 30% last quarter - Recent operating performance Welltower FFO per share: $4.50 - Trailing four-quarter funds from operations Welltower FFO growth: 18% year over year - Recent profitability trend Welltower 1-year stock performance: up 43% - Share price appreciation over the last year Welltower 5-year stock performance: up 192% - Longer-term share performance NovaGold insider purchase: 10,000 shares / $41,000 - Director Hume Kyle’s purchase Paulson stake in NovaGold: 4.55% of portfolio - NovaGold is his sixth-largest position PVH insider purchase: $1 million - CEO purchase of company stock PVH stock performance: down 30% in the last year - Despite strong margins PVH gross margin: almost 59% - Financial profile cited in comparison to peers PVH net margin: 4.63% - Operating profitability PVH sales multiple: 0.4x sales - Valuation metric Lands’ End sales multiple: 0.27x sales - Compared against PVH and Guess Lands’ End gross margin: 48% - Financial profile discussed in brand consolidation context Lands’ End net margin: 0.33% - Profitability profile Guess sales multiple: 0.21x sales - Used to compare likely acquisition attractiveness Guess gross margin: 43% - Financial profile Guess net margin: 0.47% - Financial profile Starboard stake in TripAdvisor: over 9% / about $160 million - Activist position disclosed this week TripAdvisor stock reaction: up 34% in one week - After Starboard stake disclosure Lamb Weston board expansion: from 11 to 13 members - Under cooperation agreement with JANA and Continental Grain Lifeway family ownership: 23.2% - Edward and Ludmila Smolensky’s combined stake Lifeway board proposals: 4 proposals - Family-led campaign to replace current board Krispy Kreme stock performance: down about 67% in the last year - Backdrop to CFO transition Insight market cap: $13 billion - Biotech company profile Insight net cash: about $2.8 billion - Balance sheet strength Insight share repurchase: 13% of shares outstanding - Repurchased over the last four quarters Jakafi sales (Incyte/US): $2.8 billion in 2024 - Lead drug revenue for Incyte Jakafi sales (Novartis ex-US): $1.94 billion in 2024 - Sales outside the US Ulta Beauty CFO departure: announced a day after leaving - Sudden executive exit

Pivotal Quotes: "Under the terms of the agreement, Home Depot, via SRS, will commence a cash tender offer to purchase all outstanding shares of GMS common stock for $110 per share." — Asif Suria: Announcement of the definitive GMS acquisition agreement "Concentra's playbook is to acquire struggling biotechs, many of which we like to call as zombie biotechs." — Asif Suria: Explaining the recurring strategy behind Concentra Biosciences’ biotech purchases "This truly is the saga that never quite seems to end." — Namanda Suria: Commenting on the ongoing Lifeway Foods family and board conflict

Implications: The episode suggests continued consolidation in retail, software, biotech, and brands, while activists and insiders are increasingly shaping outcomes. For listeners, the key takeaway is that balance-sheet strength, cash-rich targets, and governance pressure remain fertile hunting grounds for special situations.